Results 191 to 200 of about 54,159 (319)

Modulating the Gut Microbiome as a Therapeutic Approach in Multiple Sclerosis: Implications for Gut‐Brain Interactions and Immune Pathways: A Narrative Review

Brain and Behavior, Volume 16, Issue 2, February 2026.
The gut microbiome in multiple sclerosis (MS) shows consistent depletion of short‐chain fatty acid (SCFA)‐producing bacteria, expansion of pro‐inflammatory species, and reduced levels of butyrate, propionate, and indole metabolites. These alterations increase intestinal permeability, disrupt immune balance, and contribute to blood–brain barrier ...
Husna Irfan Thalib, Nuha Fatima, Faaleha Heba Fakruddin, Hosna Hamidullah Ali, Sariya Khan, Mohammed Talha Mohammed Zubair, Mable Pereira, Fatma E. Sayed Hassan   +7 more
wiley   +1 more source

Utilization of AhR and GPR35 Receptor Ligands as Superfoods in Cancer Prevention for Individuals with IBD. [PDF]

Int J Mol Sci
Poźniak O, Sitarz R, Sitarz MZ, Kowalczuk D, Słoń E, Dudzińska E.   +5 more
europepmc   +1 more source

Aryl hydrocarbon receptor negatively regulates LPS-induced IL-6 production through suppression of histamine production in macrophages.

International Immunology, 2011
K. Masuda, A. Kimura, Hamza Hanieh, N. Nguyen, T. Nakahama, I. Chinen, Y. Otoyo, T. Murotani, A. Yamatodani, T. Kishimoto   +9 more
semanticscholar   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li, Lili Qiao, Xinquan Liang, Yingying Zhang, Ning Liang, Jian Xie, Guodong Deng, Yuying Hao, Pingping Hu, Xue Wu, Fangjie Ding, Can Feng, Yiming Mu, Jiandong Zhang   +13 more
wiley   +1 more source

Depolymerisation of γ‐Valerolactone Organosolv Lignins with Unsupported Molybdenum‐Based Catalysts

ChemSusChem, Volume 19, Issue 3, February 2026.
Lignins from γ‐valerolactone organosolv fractionation were depolymerised in ethanol using unsupported molybdenum catalysts. Over 90% yields of low‐molecular‐weight lignin oil were obtained with minimal char formation, yields of the aromatic monomers being 7–16 wt%.
Silja Känsäkoski, Saravanan Kasipandi, Taina Ohra‐aho, Tom Wirtanen, Juha Lehtonen, David Martin Alonso, Francisco Vila, Sari Rautiainen   +7 more
wiley   +1 more source

Targeting the Aryl Hydrocarbon Receptor: The Potential of Indole Compounds in the Treatment of Cystic Fibrosis. [PDF]

Int J Mol Sci
Hou S, Yue Q, Hou X, Wu Q.
europepmc   +1 more source

Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity

Molecular Pharmacology, 2010
I. Murray, J. Morales, Colin A. Flaveny, Brett C Dinatale, C. Chiaro, Krishnegowda Gowdahalli, S. Amin, G. Perdew   +7 more
semanticscholar   +1 more source

Aryl Hydrocarbon Receptor and Stem Cells

Stem Cells International, 2017
Thomas A. Gasiewicz, Kameshwar P. Singh, Fanny L. Casado   +2 more
openaire   +3 more sources

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Activation of the aryl hydrocarbon receptor with structurally diverse ligands suppresses class switch to immunoglobulin A. [PDF]

BMC Res Notes
Costa AB, DeKrey GK.
europepmc   +1 more source